拉贝洛尔与硝苯地平治疗子痫前期疗效分析

Analysis of the Efficacy of Labelol and Nifedipine in the Treatment of Preeclampsia

目的比较拉贝洛尔和硝苯地平治疗子痫前期,观察患者血压水平、不良反应和围产结局。方法选择该院2018年7月—2019年7月收治的60例子痫前期患者,随机分为试验组、对照组,每组30例,分别给予拉贝洛尔、硝苯地平治疗,对比两组患者降压效果、不良反应及围产结局。结果治疗2 h、24 h时,试验组SBP依次为(146.2±12.5)mmHg、(140.8±11.2)mmHg,低于同期对照组的(153.6±11.6)mmHg、(145±10.9)mmHg,差异有统计学意义(t=3.651、3.254,P=0.041、0.043<0.05);治疗2 h、24 h时试验组DBP分别为(88.4±10.6)mmHg、(85.6±10.2)mmHg,和对照组(93.5±9.5)mmHg、(89.5±9.5)mmHg,经比较分析,差异有统计学意义(t=4.024、3.241,P=0.039、0.045<0.05);试验组、对照组不良反应发生率依次为20.00%、3.33%,差异有统计学意义(χ~2=3.625,P=0.038<0.05);围产不良结局发生率依次为16.67%、3.33%,差异有统计学意义(χ~2=3.021,P=0.043)。结论拉贝洛尔能更有效地控制子痫前期患者血压水平,且副反应少,能改善母婴结局。

Objective To compare the efficacy of labelolol and nifedipine in the treatment of preeclampsia,and to observe the blood pressure levels,adverse reactions and perinatal outcomes.Methods Sixty preeclampsia patients treated in our hospital from July 2018 to July 2019 were randomly divided into a test group and a control group,and 30 patients in each group were treated with labelol and nifedipine.The antihypertensive effect,adverse reactions and perinatal outcomes of the two groups of patients was compared.Results At 2 and 24 hours of treatment,the SBP of the test group was(146.2±12.5)mmHg,(140.8±11.2)mmHg,which were lower than those of the control group(153.6±11.6)mmHg and(145±10.9)mmHg.The differences were statistically significant(t=3.651,3.254,P=0.041,0.043<0.05);DBP of the test group at(2 h)and(24)h were(88.4±10.6)mmHg,(85.6±10.2)mmHg,and control group(93.5±9.5)mmHg,(89.5±9.5)mmHg.After comparative analysis,and the difference was statistically significant(t=4.024,3.241,P=0.039,0.045<0.05);the incidence of adverse reactions in the test group and the control group was 20.00%and 3.33%,respectively,with statistically significant differences(χ2=3.625,P=0.038<0.05);the incidence of perinatal adverse outcomes was 16.67%and 3.33%,respectively,with statistically significant differences(χ2=3.021,P=0.043).Conclusion Laberolol can more effectively control the blood pressure level of patients with preeclampsia,with fewer side effects,and can improve maternal and infant outcomes.